Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

BioRxiv : the Preprint Server for Biology
Fabian SchmidtPaul D Bieniasz


The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARSCoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.


Jun 28, 2020·Journal of Virology·John P Moore, P J Klasse
Dec 9, 2020·Science Translational Medicine·Zijun WangMichel C Nussenzweig
Feb 14, 2021·Science Advances·Carolina Beltrán-PavezRicardo Soto-Rifo
May 7, 2021·Nature Medicine·Carolina LucasAkiko Iwasaki
Apr 24, 2021·Science Advances·Annachiara RosaPeter Cherepanov

❮ Previous
Next ❯

Methods Mentioned

flow cytometry

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.

© 2021 Meta ULC. All rights reserved